Cancer Conference Update: A Multimedia Review of Key Presentations from the 2016 American Society of Hematology Annual MeetingAbstract 182: Phase III ALCANZA — Brentuximab vedotin demonstrates superior clinical outcomes compared to methotrexate or bexarotene in CD30-expressing cutaneous T-cell lymphoma
1:56 minutes.
TRANSCRIPTION:
DR FLOWERS: This is a trial that looked at 130 patients that were randomized either to receive B-vedotin or to receive the practitioner’s therapy of choice, where the 2 options were either bexarotene or receiving methotrexate in the study. When we look at the results comparing those 2 groups with a median follow-up of about 18 months, the response rates and the progression-free survival very strongly favored the group who got B-vedotin, with an overall response rate of 56% versus 13% and a median progression-free survival of nearly 17 months versus 3 and a half months. So this is an approach that I think, with these randomized data, suggests that B-vedotin has a role and should be applied in patients with cutaneous T-cell lymphoma. DR LOVE: Do you see patients like that yourself? DR FLOWERS: I do. So patients with cutaneous T-cell lymphoma are ones that are very challenging to treat, particularly when patients have widespread or disseminated skin disease or patients who ultimately develop Sézary syndrome. These are patients for whom a number of therapies are needed, because they very commonly progress through therapy. So my closest fungoides patients, I’m excited to see this as another therapeutic option. DR LOVE: Have you seen patients with cutaneous T-cell lymphoma who had significant responses to B-vedotin? DR FLOWERS: This has been an approach that we’ve used relatively and frequently for patients, at least in the mycosis fungoides stage. I have treated patients with cutaneous T-cell lymphoma that ultimately had nodal involvement and had progression of their disease, where I have seen responses with B-vedotin there. |